Bethany Mancilla has been promoted to senior vice president, business development at Gene Logic, where she will lead the company’s partnering and licensing efforts. Since July 2004, Ms. Mancilla has been involved in the formation and development of Gene Logic’s Drug Repositioning partnerships with pharmaceutical companies including Pfizer, Roche, Abbott, Merck-Serono, Organon, and Solvay. She is also leading the company’s efforts to secure a development partner for its proprietary drug candidate, GL1001, for inflammatory bowel disease (IBD).

Ms. Mancilla has more than 15 years of business development experience in the biotechnology sector, including more than nine years with Gene Logic. Prior to her assignment to the Drug Repositioning Business, she was responsible for spearheading the development of the company’s toxicogenomics business and, to advance the program’s development, she formed a consortium with major pharmaceutical companies such as Pfizer and Wyeth. Before joining Gene Logic, Ms. Mancilla was director of business development at BCM Technologies the venture and technology transfer subsidiary of Baylor College of Medicine, where she was involved in the creation and financing of four start-ups: GeneMedicine, Meretek Diagnostics, Sennes Drug Innovations, and Receptor Pharmaceuticals.